Login Register Cart 0
Generic placeholder image

Current Hypertension Reviews

Editor-in-Chief

ISSN (Print): 1573-4021
ISSN (Online): 1875-6506

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effect of Fixed-dose Combination Amlodipine/Valsartan in Comparison to Two Drug Combination Nebivolol/Valsartan on 24-Hour Ambulatory Blood Pressure

Author(s): Selvia M. Hanna*, Hoda M. Rabea, Mohamed E.A. Abdelrahim and Hesham B. Mahmoud

Volume 19, Issue 2, 2023

Published on: 03 May, 2023

Page: [123 - 129] Pages: 7

DOI: 10.2174/1573402119666230330082128

Price: $65

Abstract

Background: Nebivolol has a dual mechanism of action, exerting a moderate b- blockade effect and reducing peripheral arterial resistance, as a result, the antihypertensive effect of nebivolol may be higher than that of a potent vasodilator CCB such as amlodipine.

Aim: The study evaluated the effect of two nebivolol/valsartan on 24 hour ambulatory blood pressure versus amlodipine/valsartan in grade II or III hypertension patients or having uncontrolled BP despite treatment. Ambulatory blood pressure monitoring is a powerful method to monitor the changes in blood pressure over the 24 hour.

Materials and Methods: A total of 74 from 90 patients continued the study. Fourty patients received amlodipine 10 mg/valsartan 160 mg (group I), and thirty-four patients received nebivolol 5 mg/ valsartan 160 mg (group II). Peripheral blood pressure readings were measured at randomization at 6 and 12 weeks. Ambulatory blood pressure was measured at randomization and 12 weeks.

Results: Both drug combinations showed high efficacy in reducing peripheral and 24 hour ambulatory BP. There was no statistically significant difference between the groups in lowering peripheral systolic and diastolic blood pressure at 6 and 12 weeks. Furthermore, both groups failed to show any significant difference in reducing 24 hour SBP and DBP. Regarding day SBP, the blood pressure dropped by -5.63 ± 14.87 in group I and -6.25 ± 11.59 in group II (p = 0.844). Also, group I reduced the day DBP average by -2.53 ± 9.83 and group II by -3.61 ± 9.78 (p = 0.640). In addition, both drug combinations had no statistically significant difference in lowering night SBP and DBP average.

Conclusion: Both treatment groups reached the target ambulatory blood pressure, and there was no statistically significant difference between both groups as a regard reduction in all ambulatory blood pressure readings.

« Previous Next »
Graphical Abstract

[1]
Rubio-Guerra A. Current concepts in combination therapy for the treatment of hypertension: Combined calcium channel blockers and RAAS inhibitors. Integr Blood Press Control 2009; 2: 55-62.
[http://dx.doi.org/10.2147/IBPC.S6232]
[2]
Mallat S, Tanios BY, Itani HS. Current perspectives on combination therapy in the management of hypertension. Integr Blood Press Control 2013; 6: 69-78.
[http://dx.doi.org/10.2147/IBPC.S33985] [PMID: 23837009]
[3]
Schmieder RE, Volpe M, Waeber B, Ruilope LM. A guide for easy- and difficult-to-treat hypertension. Int J Cardiol 2014; 172(1): 17-22.
[http://dx.doi.org/10.1016/j.ijcard.2013.12.125] [PMID: 24456885]
[4]
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension 2010; 55(2): 399-407.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.139816] [PMID: 20026768]
[5]
de la Sierra A, Banegas JR, Vinyoles E. et al. Office and ambulatory blood pressure control in hypertensive patients treated with different two-drug and three-drug combinations. Clin Exp Hypertens 2016; 38(4): 409-14.
[http://dx.doi.org/10.3109/10641963.2016.1148160] [PMID: 27159660]
[6]
Sander GE, Fernandez C, Giles TD. Fixed-dose combination therapy of nebivolol and valsartan for the treatment of hypertension. Expert Rev Cardiovasc Ther 2016; 14(5): 563-72.
[http://dx.doi.org/10.1586/14779072.2016.1167598] [PMID: 26986445]
[7]
Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension. Blood Press 2018; 27(6): 313.
[http://dx.doi.org/10.1080/08037051.2018.1530564] [PMID: 30380927]
[8]
Neutel JM, Giles TD, Punzi H, Weiss RJ, Li H, Finck A. Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. J Am Soc Hypertens 2014; 8(12): 915-20.
[http://dx.doi.org/10.1016/j.jash.2014.09.017] [PMID: 25492835]
[9]
Pickering TG, Harshfield GA, Devereux RB, Laragh JH. What is the role of ambulatory blood pressure monitoring in the management of hypertensive patients? Hypertension 1985; 7(2): 171-7.
[http://dx.doi.org/10.1161/01.HYP.7.2.171]
[10]
Ambulatory Blood Pressure Monitoring (ABPM) For the Clinician. 2007.
[11]
Stergiou GS, Parati G, Vlachopoulos C. et al. Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement. J Hypertens 2016; 34(9): 1665-77.
[http://dx.doi.org/10.1097/HJH.0000000000000969] [PMID: 27214089]
[12]
de la Sierra A, Gorostidi M, Banegas JR. et al. Ambulatory blood pressures in hypertensive patients treated with one antihypertensive agent: Differences among drug classes and among drugs belonging to the same class. J Clin Hypertens 2015; 17(11): 857-65.
[http://dx.doi.org/10.1111/jch.12623] [PMID: 26205479]
[13]
Motozato K, Miura S, Shiga Y. et al. Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study). Clin Exp Hypertens 2016; 38(1): 45-50.
[http://dx.doi.org/10.3109/10641963.2015.1060982] [PMID: 26268636]
[14]
da Silva PM. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: Focus on amlodipine/valsartan. Clin Drug Investig 2010; 30(9): 625-41.
[http://dx.doi.org/10.2165/11538440-000000000-00000] [PMID: 20626210]
[15]
Philipp T, Smith TR, Glazer R. et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29(4): 563-80.
[http://dx.doi.org/10.1016/j.clinthera.2007.03.018] [PMID: 17617280]
[16]
Smith TR, Philipp T, Vaisse B. et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens 2007; 9(5): 355-64.
[http://dx.doi.org/10.1111/j.1524-6175.2007.06689.x] [PMID: 17485971]
[17]
Gradman AH, Basile JN, Carter BL. et al. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4(2): 90-8.
[http://dx.doi.org/10.1016/j.jash.2010.03.001] [PMID: 20400053]
[18]
Weber MA, Bakris GL, White WB, Xie L, Bharucha D, Patel M. The effects of nebivolol-valsartan single-pill combinations in reducing blood pressure in patients with stage I or II hypertension. J Am Soc Hypertens 2016; 10(S1)e8
[http://dx.doi.org/10.1016/j.jash.2016.06.023] [PMID: 27677146]
[19]
Mancia G, Fagard R, Narkiewicz K. et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2013; 31(10): 1925-38.
[http://dx.doi.org/10.1097/HJH.0b013e328364ca4c] [PMID: 24107724]
[20]
Erdogan D, Icli A, Aksoy F, Akcay S, Yucel H, Ersoy I. et al. The effect of fixed-dose combination of valsartan and amlodipine on nighttime blood pressure in patients with non-dipper hypertension. Turk Kardiyol Dern Ars 2016; 44(5): 404-13.
[http://dx.doi.org/10.5543/tkda.2015.98250] [PMID: 27439926]
[21]
Kizilirmak P, Uresin Y, Yildiz OB, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: A systematic review and meta-analysis. J Clin Hypertens 2013; 15(3): 193-200.
[http://dx.doi.org/10.1111/jch.12040] [PMID: 23458592]
[22]
Shi R, Liu K, Shi D, Liu Q, Chen X. Effects of amlodipine and valsartan on blood pressure variability and pulse wave velocity in hypertensive patients. Am J Med Sci 2017; 353(1): 6-11.
[http://dx.doi.org/10.1016/j.amjms.2016.10.005] [PMID: 28104105]
[23]
Bakris GL, Iyengar M, Lukas MA, Ordronneau P, Weber MA. Effect of combining extended-release carvedilol and lisinopril in hypertension: Results of the COSMOS study. J Clin Hypertens 2010; 12(9): 678-86.
[http://dx.doi.org/10.1111/j.1751-7176.2010.00341.x] [PMID: 20883227]
[24]
Calvo C, Ramon CH, Diana EA. Effects of nebivolol monotherapy on ambulatory blood pressure in patients with essential hypertension. Am J Hypertens 2004; 17(5): S109.
[http://dx.doi.org/10.1016/j.amjhyper.2004.03.281]
[25]
Cedeño Mora S, Macías N, Alemán Y. et al. Sp532effect of the blood pressure in morphological cerebral changes: Mri study in Ckd patients (Kidbrain). Nephrol Dial Transplant 2017; 32(S3): 308.
[http://dx.doi.org/10.1093/ndt/gfx152]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy